Loading data for AIDX — first visit, this takes a few seconds.
20/20 Biolabs Inc. (AIDX)
NasdaqCM: AIDX
· Echtzeitkurs · USD
0.55
+0.03 (5.77%)
Zum Schluss: Aug 18, 2026, 3:59 PM
0.56
+1.82%
Nachbörslich: 7:48 PM
20/20 Biolabs Inc. (AIDX) Stock Price, Analysis & Data
5.77% (1D)
| Geld | 0.61 |
| Marktkapitalisierung | 6.73 Mio |
| Umsatz (TTM) | 1.84 Mio |
| Nettogewinn (TTM) | -5.09 Mio |
| Beta | n/a |
| EPS (ttm) | -0.49 |
| KGV (TTM) | n/a |
| Forward-KGV | n/a |
| KBV (TTM) | 2.25 |
| KUV (TTM) | 3.65 |
| Earnings Date | n/a |
| Brief | 1 |
| Volumen | 208,713 |
| Ø Vol. (20D) | 800,880 |
| Eröffnung | 0.52 |
| Vortagesschluss | 0.52 |
| Tagesspanne | 0.51 - 0.56 |
| 52-Wk Range | 0.40 - 50.00 |
| Analyst | n/a |
| Kursziel | n/a |
| Dividenden | n/a |
| Ex-Dividenden-Datum | n/a |
Über AIDX
20/20 Biolabs, Inc. develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. It provides OneTest for Cancer, a multi-cancer early detection, or MCED and OneTest for Longevity, which measures inflammatory biomarkers. It also operates the Clinical Lab Innovation Axcelerator (CLIAx), a CLIA laboratory for overseas diagnostics start-ups. The company was formerly known...
Branche Medical Devices
Sektor Healthcare
IPO Datum Feb 19, 2026
Mitarbeiter 4
Börse NasdaqCM
Tickersymbol AIDX
Website https://2020biolabs.com
Finanzielle Entwicklung
Im Jahr 2025 betrug der Umsatz von 20/20 Biolabs 2.05 Mio, ein Anstieg von 16.71% im Vergleich zum Vorjahr (1.75 Mio). Der Gewinn lag bei -3.74 Mio, ein Rückgang von -32.65 %.
FinanzberichteGewinnüberraschung
20/20 Biolabs hat die Quartalszahlen am May 20, 2026 veröffentlicht:
